Skip to content

Study · Not a test of the peptide alone · 2022

3 results

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.

Liu H, Luo B, Chen X, Ingwersen SH, Jia T, Vestergård Jacobsen L, Hu P

Journal of diabetes investigation28 Dec 2021Cited by 1 (Europe PMC)

PMID34797962 (opens in a new tab)PMCIDPMC9017614 (opens in a new tab)DOI10.1111/jdi.13716 (opens in a new tab)PepBankPUB-34797962
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    In a population pharmacokinetic analysis of Chinese individuals with type 2 diabetes, liraglutide exposure was inversely correlated with bodyweight.

    In plain wordsIn Chinese adults with type 2 diabetes, people with higher body weight had lower liraglutide exposure.

    Peptide
    Liraglutide
    Outcome
    Not applicableCovariate effect of bodyweight on liraglutide exposure
    Study

    n = 720

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Although there were no relevant covariate effects on degludec exposure, liraglutide exposure was inversely correlated with bodyweight.
    2 context sentences
    Summary · context
    Furthermore, we report a population pharmacokinetic analysis of a 26-week, phase III, treat-to-target, randomized trial of 720 Chinese individuals with type 2 diabetes.
    Summary · context
    We report the findings of a single-dose, randomized, three-period cross-over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    In healthy Chinese individuals, the pharmacokinetic profiles of the fixed-ratio combination IDegLira were similar to those of its individual components.

    In plain wordsIn healthy Chinese adults, the combined product IDegLira behaved in the body like its two parts given separately.

    Peptide
    Liraglutide
    Outcome
    No significant changePharmacokinetic profile of IDegLira versus its components
    Study

    n = 24

    Comparator
    Individual components (insulin degludec and liraglutide)
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The pharmacokinetic profiles of IDegLira were similar to its individual components.
    1 context sentence
    Summary · context
    We report the findings of a single-dose, randomized, three-period cross-over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialPharmacokinetics

    Dose proportionality was indicated for both IDegLira components, including liraglutide.

    In plain wordsExposure to both parts of IDegLira, including liraglutide, rose in proportion to dose.

    Peptide
    Liraglutide
    Outcome
    Not applicableDose proportionality of IDegLira components
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Dose proportionality was indicated for both IDegLira components.
    1 context sentence
    Summary · context
    We report the findings of a single-dose, randomized, three-period cross-over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.